EC-18
Sponsors
Enzychem Lifesciences Corporation
Conditions
Atopic DermatitisCOVID-19Chemotherapy-Induced NeutropeniaChemotherapy-induced NeutropeniaCovid19 PneumoniaFebrile NeutropeniaStomatitis
Phase 1
A Safety and PK Study of EC-18 in Healthy Subjects
CompletedNCT02496143
Start: 2015-07-31End: 2015-12-31Updated: 2016-01-11
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
CompletedNCT02532712
Start: 2015-03-31End: 2015-12-31Updated: 2016-01-27
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
CompletedNCT02700360
Start: 2015-08-31End: 2015-10-31Updated: 2016-03-15
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
CompletedNCT03104595
Start: 2017-10-30End: 2019-12-05Updated: 2023-08-15
Phase 2
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
CompletedNCT03200340
Start: 2018-07-03End: 2021-05-14Updated: 2023-07-27
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
CompletedNCT04500132
Start: 2020-05-28End: 2021-02-15Updated: 2022-02-10
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
NCT04569227
Start: 2021-04-30End: 2021-11-30Target: 60Updated: 2021-06-10
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
Not yet recruitingNCT06487000
Start: 2025-05-31End: 2026-12-31Target: 150Updated: 2024-11-08